Stryker Corporation (SYK)
Stryker Corporation (SYK) is a leading medical technology company specializing in innovative medical and surgical products, orthopedics, neurotechnology, and spine solutions. Founded in 1941, Stryker develops a wide range of devices used in hospitals and healthcare facilities worldwide to improve patient outcomes and support healthcare providers.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 31, 2025 | $0.84 | 2025-09-30 | 2025-09-30 |
| July 31, 2025 | $0.84 | 2025-06-30 | 2025-06-30 |
| April 30, 2025 | $0.84 | 2025-03-31 | 2025-03-31 |
| January 31, 2025 | $0.84 | 2024-12-31 | 2024-12-31 |
| October 31, 2024 | $0.80 | 2024-09-30 | 2024-09-30 |
Dividends Summary
- Stryker Corporation has issued 70 dividend payments over the past 20 years
- The most recent dividend was paid 4 days ago, on October 31, 2025
- The highest dividend payed out to investors during this period was $0.84 per share
- The average dividend paid during this period was $0.45 per share.
Company News
The US neurology devices market is projected to grow from $3.75 billion in 2024 to $6.89 billion by 2033, driven by rising neurological disorder prevalence, technological advancements, and government R&D support.
Fenimore Asset Management completely sold its entire 243,780 shares of Waters Corporation, valued at $85.09 million, representing a full exit from the position during Q3 2025. The sale reflects a strategic portfolio shift amid challenging market conditions for laboratory instrumentation stocks.
Perimeter Medical Imaging AI reported preliminary Q2 2025 revenues of $500,000, representing 100% year-over-year growth. The company reduced operating costs by 30%, appointed new leadership, and created an Industry Advisory Board to support future growth strategies.
Stryker reported $5.42 billion in revenue for Q2 2024, a year-over-year increase of 8.5%, and EPS of $2.81 compared to $2.54 a year ago. The company's performance across various business segments and geographies was in line with or exceeded analyst estimates.
